What is IBRX stock price today?

IBRX (Immunitybio Inc) stock is trading at $8.20 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is IBRX stock going up or down today?

IBRX stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy IBRX stock now?

The decision to buy IBRX depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is IBRX a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for IBRX based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is IBRX stock overvalued or undervalued?

Use our DCF valuation calculator to determine if IBRX is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is IBRX's P/E ratio?

P/E ratio data for IBRX will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is IBRX's market cap?

IBRX (Immunitybio Inc) has a market capitalization of $7.95 billion, making it a small-cap stock.

What is IBRX's price to book ratio?

Price-to-book ratio for IBRX is available on our dashboard along with other valuation metrics.

Does IBRX pay dividends?

IBRX does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is IBRX's dividend yield?

IBRX does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is IBRX stock a good long-term investment?

IBRX's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is IBRX's revenue growth rate?

IBRX has shown revenue growth of 4.1% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Profitability metrics for IBRX are available on our dashboard with complete income statement analysis.

What are the risks of investing in IBRX?

Key risks for IBRX include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does IBRX compare to its competitors?

Compare IBRX to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize IBRX's performance and positioning.

What is IBRX's stock price target for 2026?

Our AI model provides price targets for IBRX based on fundamental analysis: Bull case $10.66 (+30%), Base case $9.43 (+15%), Bear case $7.38 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about IBRX?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for IBRX. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is IBRX's next earnings report?

IBRX reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

IBRX - Immunitybio Inc

NYSE * Health Care * Biotechnology

$8.20

+$0.50 (+6.49%)

About Immunitybio Inc

ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California.

IBRX Key Statistics

Market Cap

$7.95B

EPS

$-0.38

Revenue Growth

+4.1%

Employees

684

How IBRX Compares to Peers

IBRX has the fastest revenue growth among competitors

IBRX is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
IBRX(This stock)	$7.95B	N/A	4%	0.0%	-
AMGNAmgen Inc	$191.53B	24.9	0%	0.2%	vs AMGN
GILDGilead Sciences	$170.84B	20.3	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$112.22B	28.8	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$79.35B	18.1	0%	0.3%	vs REGN
BIIBBiogen Inc	$26.91B	20.9	-0%	0.1%	vs BIIB

Immunitybio Inc Company Information

Headquarters: California; U.S.A
Website: immunitybio.com
Sector: Health Care
Industry: Biotechnology

IBRX - Immunitybio Inc

About Immunitybio Inc

IBRX Key Statistics

How IBRX Compares to Peers

Immunitybio Inc Company Information

IBRX Lician Score

IBRX Financial Snowflake

Upcoming Events for IBRX